-
Cabozantinib, sold
under the
brand names Cometriq and
Cabometyx among others, is an anti-cancer
medication used to
treat medullary thyroid cancer, renal...
-
partnered its lead
cancer drug candidate, XL-184 (which
would become called cabozantinib) and
another cancer candidate, XL-281, with
Bristol Myers Squibb; BMS...
- surgery.
Cabozantinib,
trade name Cometriq, was
granted marketing approval (November 2012) by the U.S. FDA for this indication.
Cabozantinib which is...
- daclatasvir, sofosbuvir, afatinib, axitinib, brigatinib, baricitinib,
cabozantinib, dasatinib, neratinib, eltrombopag, ibrutinib, lenvatinib, palbociclib...
-
common adverse reaction to
cytotoxic chemotherapy drugs,
particularly cabozantinib, cytarabine,
doxorubicin (including
pegylated liposomal doxorubicin,...
- c-Met
inhibitors are currently[when?] in
clinical trials.
Crizotinib and
cabozantinib were the
first to be
approved by the U.S. FDA.
Crizotinib received accelerated...
- that it is due to the
decreased absorption of
abacavir by orlistat.
Cabozantinib:
Drugs from the MRP2
inhibitor (Multidrug resistance-****ociated protein...
-
spasticity in
children aged two
years and older. In 2016,
Ipsen licensed cabozantinib from Exelixis,
which received marketing authorization the same year for...
- cell
carcinoma over
everolimus in 2015 and was
approved by the FDA.
Cabozantinib also
demonstrated an
overall survival benefit over
everolimus and was...
-
cancer (MTC) who
require systemic therapy following prior treatment with
cabozantinib and/or vandetanib. In
September 2024, the FDA
granted traditional approval...
